Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.40 |
| ▸ | NOS3 | P29474 | 4/20 | 0.40 |
| ▸ | NOS2 | P35228 | 4/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032124 | 0.78 | NOS1 (0.40) | NOS1NOS3NOS2MEN1KMT2A | |
| SCHEMBL5542352 | 0.72 | S100A4 (0.33) | NOS1NOS3NOS2S100A4MEN1 | |
| SCHEMBL15551123 | 0.71 | NOS1 (0.43) | NOS1NOS3NOS2KMT2A | |
| SCHEMBL28595766 | 0.69 | NOS3 (0.36) | NOS1NOS3NOS2 | |
| SCHEMBL28095819 | 0.66 | KDM4E (0.37) | MEN1KMT2A | |
| SCHEMBL11244859 | 0.64 | NOS1 (0.33) | NOS1NOS3NOS2 | |
| SCHEMBL12352022 | 0.64 | NOS1 (0.37) | NOS1NOS3NOS2 | |
| SCHEMBL13945520 | 0.64 | NOS1 (0.37) | NOS1NOS3NOS2 | |
| SCHEMBL12427427 | 0.63 | NOS1 (0.36) | NOS1NOS3NOS2MEN1KMT2A | |
| SCHEMBL12037658 | 0.62 | GAA (0.65) | NOS1NOS3NOS2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177176-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |